Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 20.05
-1.04 (-4.93%)
Oct 23, 2026, 11:29 AM CST
Nanjing Vazyme Biotech Revenue
Nanjing Vazyme Biotech had revenue of 379.80M CNY in the quarter ending June 30, 2026, with 18.23% growth. This brings the company's total for the last twelve months to 1.47B, up 10.28% year-over-year. In the year 2025, Nanjing Vazyme Biotech had annual revenue of 1.38B. That makes Nanjing Vazyme Biotech the 16,752nd largest company in the world by revenue and 3,024th in China.
Revenue (ttm)
1.47B
Revenue Growth
+10.28%
P/S Ratio
7.41
Revenue / Employee
490.38K
Employees
3,002
Market Cap
10.37B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Nanjing Vazyme Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.38B | -16.98K | - |
| Dec 31, 2024 | 1.38B | 91.91M | 7.15% |
| Dec 31, 2023 | 1.29B | -2.28B | -63.97% |
| Dec 31, 2022 | 3.57B | 1.70B | 90.99% |
| Dec 31, 2021 | 1.87B | 304.17M | 19.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Anhui Anke Biotechnology (Group) | 2.45B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.53B |
| Shanghai Medicilon | 1.38B |
| BrightGene Bio-Medical Technology | 1.36B |
| Hualan Biological Vaccine | 1.19B |